A new report from British market research firm Deep Pharma Intelligence provides a profile of the use of artificial intelligence in the drug discovery industry.
The company said its report provides an “in-depth overview of the current industry landscape with interactive profiles of 1,900 investors, 90 corporations, and 50 hubs.”
Around 800 companies are identified with a focus on AI, 91 of which were established last year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze